Corcept Other Non Cash Items vs Change In Cash Analysis

CORT Stock

USD 30.17 1.04 3.33%

Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics Other Non Cash Items and its Change In Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Other Non Cash Items vs Change In Cash

Other Non Cash Items vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics Other Non Cash Items account and Change In Cash. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Corcept Therapeutics' Other Non Cash Items and Change In Cash is -0.68. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' Other Non Cash Items and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Corcept Therapeutics Incorporated are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Other Non Cash Items i.e., Corcept Therapeutics' Other Non Cash Items and Change In Cash go up and down completely randomly.

Correlation Coefficient

-0.68

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Other Non Cash Items

Change In Cash

Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024

	2021	2022	2023	2024 (projected)
Other Operating Expenses	241.5M	289.2M	375.1M	393.8M
Research Development	113.9M	131.0M	184.4M	193.6M

Other Operating Expenses Research Development

Corcept Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Short Term Investments	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Current Deferred Revenue
Total Assets		0.32	0.75	0.93	0.74	0.86	0.82	0.5	0.98	1.0	0.85	0.4	-0.16	0.93	-0.57	0.51	-0.76	0.9	0.86	0.96	0.97	0.52	0.03	0.46	0.99	0.91
Other Current Liab	0.32		0.34	0.24	0.5	0.16	0.15	0.34	0.27	0.34	0.44	0.3	0.14	0.49	-0.18	0.36	-0.5	0.22	0.23	0.36	0.34	0.28	-0.41	0.25	0.33	0.38
Total Current Liabilities	0.75	0.34		0.87	0.19	0.92	0.91	0.32	0.81	0.7	0.75	0.17	-0.36	0.6	-0.31	0.11	-0.22	0.75	0.91	0.69	0.6	0.36	-0.37	0.0	0.66	0.65
Accounts Payable	0.93	0.24	0.87		0.48	0.93	0.89	0.43	0.94	0.91	0.89	0.33	-0.23	0.79	-0.57	0.3	-0.51	0.87	0.97	0.83	0.83	0.47	-0.08	0.24	0.87	0.87
Cash	0.74	0.5	0.19	0.48		0.33	0.31	0.55	0.64	0.78	0.52	0.53	0.23	0.87	-0.4	0.74	-1.0	0.54	0.31	0.77	0.86	0.52	0.23	0.73	0.82	0.69
Other Current Assets	0.86	0.16	0.92	0.93	0.33		0.95	0.31	0.91	0.82	0.78	0.16	-0.47	0.68	-0.49	0.11	-0.36	0.91	0.94	0.83	0.75	0.36	-0.1	0.03	0.8	0.74
Total Liab	0.82	0.15	0.91	0.89	0.31	0.95		0.43	0.88	0.76	0.68	0.27	-0.32	0.64	-0.35	0.13	-0.34	0.8	0.88	0.83	0.72	0.48	0.0	0.05	0.76	0.65
Common Stock	0.5	0.34	0.32	0.43	0.55	0.31	0.43		0.44	0.48	0.33	0.97	0.54	0.47	0.12	0.36	-0.53	0.18	0.33	0.56	0.51	0.99	0.16	0.33	0.51	0.5
Property Plant Equipment	0.98	0.27	0.81	0.94	0.64	0.91	0.88	0.44		0.97	0.83	0.31	-0.24	0.9	-0.53	0.44	-0.67	0.92	0.88	0.94	0.94	0.47	0.01	0.39	0.96	0.86
Total Stockholder Equity	1.0	0.34	0.7	0.91	0.78	0.82	0.76	0.48	0.97		0.86	0.39	-0.15	0.95	-0.59	0.56	-0.8	0.9	0.82	0.94	0.98	0.5	0.02	0.51	0.99	0.93
Other Assets	0.85	0.44	0.75	0.89	0.52	0.78	0.68	0.33	0.83	0.86		0.29	-0.18	0.77	-0.6	0.39	-0.55	0.79	0.91	0.74	0.76	0.36	-0.35	0.3	0.79	0.95
Common Stock Shares Outstanding	0.4	0.3	0.17	0.33	0.53	0.16	0.27	0.97	0.31	0.39	0.29		0.69	0.39	0.19	0.4	-0.5	0.03	0.24	0.44	0.42	0.94	0.13	0.37	0.41	0.48
Other Stockholder Equity	-0.16	0.14	-0.36	-0.23	0.23	-0.47	-0.32	0.54	-0.24	-0.15	-0.18	0.69		-0.01	0.5	0.42	-0.19	-0.57	-0.32	-0.17	-0.08	0.49	0.06	0.46	-0.12	-0.04
Short Term Investments	0.93	0.49	0.6	0.79	0.87	0.68	0.64	0.47	0.9	0.95	0.77	0.39	-0.01		-0.51	0.69	-0.89	0.79	0.68	0.9	0.97	0.47	0.01	0.65	0.96	0.84
Short Long Term Debt Total	-0.57	-0.18	-0.31	-0.57	-0.4	-0.49	-0.35	0.12	-0.53	-0.59	-0.6	0.19	0.5	-0.51		-0.21	0.45	-0.71	-0.52	-0.49	-0.55	0.09	-0.16	-0.17	-0.55	-0.56
Property Plant And Equipment Net	0.51	0.36	0.11	0.3	0.74	0.11	0.13	0.36	0.44	0.56	0.39	0.4	0.42	0.69	-0.21		-0.73	0.26	0.2	0.47	0.61	0.33	-0.03	0.98	0.58	0.52
Net Debt	-0.76	-0.5	-0.22	-0.51	-1.0	-0.36	-0.34	-0.53	-0.67	-0.8	-0.55	-0.5	-0.19	-0.89	0.45	-0.73		-0.58	-0.35	-0.79	-0.88	-0.49	-0.22	-0.72	-0.84	-0.71
Retained Earnings	0.9	0.22	0.75	0.87	0.54	0.91	0.8	0.18	0.92	0.9	0.79	0.03	-0.57	0.79	-0.71	0.26	-0.58		0.83	0.87	0.85	0.22	0.01	0.2	0.88	0.79
Non Current Assets Total	0.86	0.23	0.91	0.97	0.31	0.94	0.88	0.33	0.88	0.82	0.91	0.24	-0.32	0.68	-0.52	0.2	-0.35	0.83		0.75	0.72	0.39	-0.26	0.12	0.77	0.85
Non Currrent Assets Other	0.96	0.36	0.69	0.83	0.77	0.83	0.83	0.56	0.94	0.94	0.74	0.44	-0.17	0.9	-0.49	0.47	-0.79	0.87	0.75		0.96	0.57	0.15	0.41	0.96	0.83
Cash And Short Term Investments	0.97	0.34	0.6	0.83	0.86	0.75	0.72	0.51	0.94	0.98	0.76	0.42	-0.08	0.97	-0.55	0.61	-0.88	0.85	0.72	0.96		0.52	0.14	0.58	1.0	0.86
Common Stock Total Equity	0.52	0.28	0.36	0.47	0.52	0.36	0.48	0.99	0.47	0.5	0.36	0.94	0.49	0.47	0.09	0.33	-0.49	0.22	0.39	0.57	0.52		0.15	0.31	0.53	0.52
Non Current Liabilities Total	0.03	-0.41	-0.37	-0.08	0.23	-0.1	0.0	0.16	0.01	0.02	-0.35	0.13	0.06	0.01	-0.16	-0.03	-0.22	0.01	-0.26	0.15	0.14	0.15		0.06	0.1	-0.16
Property Plant And Equipment Gross	0.46	0.25	0.0	0.24	0.73	0.03	0.05	0.33	0.39	0.51	0.3	0.37	0.46	0.65	-0.17	0.98	-0.72	0.2	0.12	0.41	0.58	0.31	0.06		0.53	0.45
Total Current Assets	0.99	0.33	0.66	0.87	0.82	0.8	0.76	0.51	0.96	0.99	0.79	0.41	-0.12	0.96	-0.55	0.58	-0.84	0.88	0.77	0.96	1.0	0.53	0.1	0.53		0.89
Current Deferred Revenue	0.91	0.38	0.65	0.87	0.69	0.74	0.65	0.5	0.86	0.93	0.95	0.48	-0.04	0.84	-0.56	0.52	-0.71	0.79	0.85	0.83	0.86	0.52	-0.16	0.45	0.89

Click cells to compare fundamentals

Corcept Therapeutics Account Relationship Matchups

Corcept Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Current Liab	30.1M	(2.1M)	(526K)	68.5M	654K	621.3K
Total Current Liabilities	41.1M	10.6M	6.9M	81.6M	104.5M	109.7M
Accounts Payable	7.5M	10.6M	6.9M	12.0M	17.4M	18.3M
Cash	315.3M	476.9M	335.8M	436.6M	135.6M	116.6M
Other Current Assets	6.0M	6.7M	10.3M	16.4M	27.6M	28.9M
Total Liab	41.1M	48.4M	48.0M	81.6M	114.8M	120.6M
Common Stock	120K	122K	127K	131K	133K	85.9K
Property Plant Equipment	1.1M	1.7M	1.0M	1.8M	2.0M	2.1M
Total Stockholder Equity	371.2M	523.3M	375.8M	501.8M	506.7M	532.0M
Other Assets	61.1M	52.9M	43.5M	77.5M	89.1M	93.5M
Common Stock Shares Outstanding	122.6M	124.2M	126.0M	116.0M	111.7M	83.1M
Liabilities And Stockholders Equity	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Stockholder Equity	394.4M	440.3M	180.9M	206.2M	103.4M	98.3M
Short Term Investments	244.7M	364.5M	145.9M	365.3M	232.7M	244.3M
Property Plant And Equipment Net	3.4M	2.5M	514K	1.1M	315K	559.2K
Net Debt	(311.9M)	(474.3M)	(335.3M)	(435.5M)	(135.4M)	(142.2M)
Retained Earnings	(23.6M)	82.5M	195.0M	296.4M	402.5M	422.7M
Non Current Assets Total	59.7M	47.5M	42.4M	84.7M	162.9M	171.0M
Non Currrent Assets Other	10.5M	13.4M	14.4M	17.2M	14.8M	15.5M
Cash And Short Term Investments	315.3M	476.9M	335.8M	436.6M	368.2M	386.6M
Common Stock Total Equity	117K	120K	122K	127K	146.1K	87.7K
Non Current Liabilities Total	1.9M	37.8M	41.0M	9.1M	10.3M	12.7M
Property Plant And Equipment Gross	4.5M	4.2M	514K	1.1M	315K	299.3K
Total Current Assets	352.6M	524.2M	381.4M	498.7M	458.6M	481.6M
Accumulated Other Comprehensive Income	261K	415K	(227K)	(869K)	609K	639.5K
Net Tangible Assets	371.2M	523.3M	375.8M	501.8M	577.1M	606.0M
Retained Earnings Total Equity	(117.7M)	(23.6M)	82.5M	195.0M	224.2M	235.4M
Capital Surpluse	417.2M	457.1M	516.1M	591.3M	680.1M	426.4M
Inventory	17.4M	21.2M	18.0M	17.0M	7.7M	9.6M
Net Receivables	19.9M	26.2M	27.6M	45.1M	55.1M	57.9M
Net Invested Capital	371.2M	523.3M	375.8M	501.8M	506.7M	431.5M
Long Term Investments	39.4M	36.2M	112.3M	4.9M	57.2M	41.7M

Pair Trading with Corcept Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Corcept Stock

0.86	NPCE	Neuropace	Pair Corr
0.61	PPERY	Bank Mandiri Persero	Pair Corr
0.58	FNA	Paragon 28	Pair Corr
0.58	PPERF	Bank Mandiri Persero	Pair Corr
0.54	BKRKY	Bank Rakyat	Pair Corr

The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.

The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Corcept Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corcept Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corcept Therapeutics Incorporated Stock. Highlighted below are key reports to facilitate an investment decision about Corcept Therapeutics Incorporated Stock:

How To Invest In Corcept

Details

Is Corcept Stock a good investment?

Details

What is Corcept Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Corcept Stock analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.786

Earnings Share

1.04

Revenue Per Share

5.118

Quarterly Revenue Growth

0.39

Return On Assets

0.1197

The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Corcept Other Non Cash Items vs Change In Cash Analysis

Other Non Cash Items vs Change In Cash

Other Non Cash Items vs Change In Cash Correlation Analysis

Correlation Coefficient

Other Non Cash Items

Change In Cash

Corcept Therapeutics fundamental ratios Correlations

Corcept Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Corcept Therapeutics fundamental ratios Accounts

Pair Trading with Corcept Therapeutics

Moving against Corcept Stock

Complementary Tools for Corcept Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Common Stock
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant Equipment	+ 0.98	Total Assets

Net Debt	- 1.0	Cash
Net Debt	- 0.89	Short Term Investments
Cash And Short Term Investments	- 0.88	Net Debt
Total Current Assets	- 0.84	Net Debt
Net Debt	- 0.8	Total Stockholder Equity
Non Currrent Assets Other	- 0.79	Net Debt